Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.

被引：24
|
作者：
Sikic, B. I.
Eckhardt, S. G.
Gallant, G.
Burris, H. A.
Camidge, D. R.
Colevas, A. D.
Jones, S. F.
Messersmith, W. A.
Wakelee, H. A.
Li, H.
Kaminker, P. G.
Morris, S.
Infante, J. R.
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Univ Colorado, Sch Med, Aurora, CO USA
[3] Human Genome Sci, Rockville, MD USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Colorado Denver, Aurora, CO USA
[6] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[7] Univ Colorado, Ctr Canc, Aurora, CO USA
[8] Aegera Therapeut, Montreal, PQ, Canada
[9] Sarah Cannon Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3008
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.
    Eckhardt, S. G.
    Gallant, G.
    Sikic, B. I.
    Camidge, D. R.
    Burris, H. A., III
    Wakelee, H. A.
    Messersmith, W. A.
    Jones, S. F.
    Colevas, A. D.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of AMG 706 in patients (pts) with advanced solid tumors
    Herbst, R.
    Kurzrock, R.
    Parson, M.
    Mulay, M.
    Purdom, M.
    Eschenberg, M.
    Wong, S.
    Xu, R.
    Wathen, L.
    Rosen, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 421 - 421
  • [3] Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.
    Tolcher, Anthony W.
    Papadopoulos, Kyriakos P.
    Patnaik, Amita
    Fairbrother, Wayne J.
    Wong, Harvey
    Budha, Nageshwar R.
    Darbonne, Walter C.
    Peale, Franklin V.
    Mamounas, Michael J.
    Royer-Joo, Stephanie
    Yu, Ron
    Portera, Chia C.
    Bendell, Johanna C.
    Burris, Howard A.
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] PHASE I AND PHARMACOKINETICS/PHARMACODYNAMICS (PK/PD) STUDY OF MEK INHIBITOR, RO4987655, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Nakamichi, S.
    Nokihara, H.
    Yamamoto, N.
    Tamura, Y.
    Honda, K.
    Wakui, H.
    Yamada, Y.
    Yamazaki, N.
    Suzuki, S.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 156 - 156
  • [5] Phase I and pharmacokinetics/pharmacodynamics (PK/PD) study of MEK inhibitor, RO4987655, in Japanese patients with advanced solid tumors.
    Yamada, Yasuhide
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Fujiwara, Yutaka
    Tamura, Yosuke
    Wakui, Hiroshi
    Honda, Kazunori
    Nakamichi, Shinji
    Asahina, Hajime
    Tanabe, Yuko
    Kitazono, Satoru
    Mizugaki, Hidenori
    Yamazaki, Naoya
    Suzuki, Shigenobu
    Sasaki, Junichi
    Matsuoka, Mieko
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] Pharmacokinetics (PK) and pharmacodynamics (PD) of RO4929097 (RO), a novel gamma secretase inhibitor, in a phase I study in patients with advanced solid tumors
    Wang, Karen
    DRUG METABOLISM REVIEWS, 2010, 42 : 272 - 273
  • [7] Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of patupilone and warfarin in patients (pts) with advanced solid tumors: An open-label, phase I study
    Takimoto, C. H.
    Fu, S.
    Dhillon, N.
    Mita, M. M.
    Mita, A. C.
    Cheung, W.
    Xu, Y.
    Ali, A.
    Johri, A.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    Dy, Grace K.
    Zhao, Yujie
    Ma, Wen Wee
    Opyrchal, Mateusz
    Bakhribah, Hatoon
    Jacob, Sandra M.
    O'Hara, Corrie
    Dozier, Askia
    Cmiljanovic, Natasa
    Todaro, Barbara
    Brady, William E.
    Schmitz, Debora
    Dimitrijevic, Sasa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
    Papadopoulos, K. P.
    Markman, B.
    Tabernero, J.
    Patnaik, A.
    Heath, E. I.
    DeCillis, A.
    Laird, D.
    Aggarwal, S. K.
    Nguyen, L.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti -tumor activity of oral COH29, a novel ribonucleotide reductase (RNR) inhibitor in adult patients (pts) with advanced solid tumors.
    Chao, Joseph
    Synold, Timothy W.
    Frankel, Paul Henry
    Mortimer, Joanne E.
    Chung, Vincent M.
    Smith, D. Lynne
    Nallu, Rajiv
    Pillai, Raju K.
    Simpson, James
    Horne, David
    Kwak, Larry W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345